Cargando…

TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases

Modern vaccines have largely shifted from using whole, killed or attenuated pathogens to being based on subunit components. Since this diminishes immunogenicity, vaccine adjuvants that enhance the immune response to purified antigens are critically needed. Further advantages of adjuvants include dos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luchner, Marina, Reinke, Sören, Milicic, Anita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911620/ https://www.ncbi.nlm.nih.gov/pubmed/33499143 http://dx.doi.org/10.3390/pharmaceutics13020142

Ejemplares similares

Inflammasome-Mediated Immunogenicity of Clinical and Experimental Vaccine Adjuvants
por: Reinke, Sören, et al.
Publicado: (2020)

Small Cationic DDA:TDB Liposomes as Protein Vaccine Adjuvants Obviate the Need for TLR Agonists in Inducing Cellular and Humoral Responses
por: Milicic, Anita, et al.
Publicado: (2012)

Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
por: Bhatnagar, Shubhmita, et al.
Publicado: (2022)

Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases
por: Yang, Jing-Xing, et al.
Publicado: (2022)

A novel defined TLR3 agonist as an effective vaccine adjuvant
por: Ko, Kwang Hyun, et al.
Publicado: (2023)

Advances in Infectious Disease Vaccine Adjuvants
por: Fan, Jingyi, et al.
Publicado: (2022)

BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant
por: Kaushik, Deepender, et al.
Publicado: (2020)

Combination of TLR2 and TLR3 agonists derepress infectious bursal disease virus vaccine-induced immunosuppression in the chicken
por: Bashir, Khalid, et al.
Publicado: (2019)

The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
por: Demaria, Sandra, et al.
Publicado: (2013)

An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants
por: Kayesh, Mohammad Enamul Hoque, et al.
Publicado: (2021)

Recent Advances of Vaccine Adjuvants for Infectious Diseases
por: Lee, Sujin, et al.
Publicado: (2015)

Vaccine adjuvant materials for cancer immunotherapy and control of infectious disease
por: Lim, Yong Taik
Publicado: (2015)

OMV Vaccines and the Role of TLR Agonists in Immune Response
por: Mancini, Francesca, et al.
Publicado: (2020)

Molecular Signatures of a TLR4 Agonist-Adjuvanted HIV-1 Vaccine Candidate in Humans
por: Anderson, Jenna, et al.
Publicado: (2018)

New Glucosamine-Based TLR4 Agonists: Design, Synthesis, Mechanism of Action, and In Vivo Activity as Vaccine Adjuvants
por: Romerio, Alessio, et al.
Publicado: (2023)

Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine
por: Zhou, Shi-Hao, et al.
Publicado: (2022)

Vaccines and Vaccine Adjuvants for Infectious Diseases and Autoimmune Diseases
por: Nandakumar, Kutty Selva
Publicado: (2023)

TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious Disease
por: Mifsud, Edin J., et al.
Publicado: (2014)

Synthetic glycan-based TLR4 agonists targeting caspase-4/11 for the development of adjuvants and immunotherapeutics
por: Adanitsch, Florian, et al.
Publicado: (2018)

A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93
por: Orr, Mark T., et al.
Publicado: (2014)

THEME: “Vaccines and Vaccine Adjuvants/Immunomodulators for Infectious Diseases”
por: Retnakumar, Sruthi Vijaya, et al.
Publicado: (2023)

Trial watch: TLR3 agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

TLR3 and TLR9 Agonists Improve Postexposure Vaccination Efficacy of Live Smallpox Vaccines
por: Israely, Tomer, et al.
Publicado: (2014)

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
por: Cauwelaert, Natasha Dubois, et al.
Publicado: (2016)

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines
por: Van Hoeven, Neal, et al.
Publicado: (2017)

Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination
por: Dowling, David J., et al.
Publicado: (2022)

RIG-I and TLR-7/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine
por: Jangra, Sonia, et al.
Publicado: (2022)

Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines
por: Rapaka, Rekha R., et al.
Publicado: (2021)

Differential Adjuvant Activities of TLR7 and TLR9 Agonists Inversely Correlate with Nitric Oxide and PGE(2) Production
por: Lee, Jinhee, et al.
Publicado: (2015)

Using distinct molecular signatures of human monocytes and dendritic cells to predict adjuvant activity and pyrogenicity of TLR agonists
por: Kamgang, Richard Kenmoe, et al.
Publicado: (2008)

Vaccine Formulation for Infectious Diseases and Adjuvant Mechanisms of Action
por: Wilson, Heather L., et al.
Publicado: (2021)

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
por: Frega, Giorgio, et al.
Publicado: (2020)

Skin scarification with Plasmodium falciparum peptide vaccine using synthetic TLR agonists as adjuvants elicits malaria sporozoite neutralizing immunity
por: Mitchell, Robert A., et al.
Publicado: (2016)

The TLR4 agonist adjuvant SLA-SE promotes functional mucosal antibodies against a parenterally delivered ETEC vaccine
por: Liang, Hong, et al.
Publicado: (2019)

The Role of TLR2 in Infectious Diseases Caused by Mycobacteria: From Cell Biology to Therapeutic Target
por: Hu, Wanbin, et al.
Publicado: (2022)

Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria
por: Milicic, Anita, et al.
Publicado: (2017)

Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice
por: Buffa, Viviana, et al.
Publicado: (2012)

Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms
por: Reinke, Sören, et al.
Publicado: (2023)

Targeting TLR2 for Vaccine Development
por: Basto, Afonso P., et al.
Publicado: (2014)

Self-Assembled TLR7/8 Agonist-Mannose Conjugate as An Effective Vaccine Adjuvant for SARS-CoV-2 RBD Trimer
por: Teng, Changcai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kheb5q9q3vlbp835b3m4lketkk